In addition, our results further support anti-tumor immunity as a major mechanism of action of anti-HER2 antibodies in some patients, backing the potential of TI- NK cells or TI-NK cell surrogates as biomarkers of response in primary HER2-positive  breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.